Executive Director, Oncology Global Commercial Strategy – Oncology at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, OncologyIndustries

Requirements

Minimum 12 years of experience in the pharmaceutical/biotech industry, with significant experience in oncology
Bachelor’s degree required; advanced degree (MBA, PhD, PharmD, MD) preferred
Proven track record in global commercial strategy, product launch, and lifecycle management
Strong strategic thinking, analytical, and leadership skills
Experience working in a matrixed, global environment
Excellent communication and influencing skills
Deep understanding of breast cancer and/or other solid tumor markets (preferred)
Experience with early asset strategy and clinical development input (preferred)
Familiarity with global pricing, access, and reimbursement dynamics (preferred)

Responsibilities

Develop and lead global commercial strategies for breast and other tumor indications, ensuring alignment with R&D, Medical Affairs, Market Access, and regional commercial teams
Drive asset strategy from early development through launch and lifecycle management
Partner with Global Product Teams (GPTs), Global Medical, Regulatory, and Market Access to ensure integrated planning and execution
Serve as the commercial lead on cross-functional governance bodies and decision-making forums
Lead global market assessments, competitive intelligence, and customer insights to inform strategic decisions
Oversee development of global forecasts and business cases for pipeline and inline assets
Drive global launch readiness planning and execution for new indications and geographies
Ensure alignment with regional and affiliate teams to optimize launch success
Engage with external stakeholders including key opinion leaders (KOLs), patient advocacy groups, and payers to shape strategy and value propositions
Represent commercial perspective in investor and partner discussions as needed

Skills

Commercial Strategy

Oncology

Lifecycle Management

Market Access

Forecasting

Competitive Intelligence

Cross-Functional Collaboration

Strategic Leadership

Breast Cancer

Solid Tumors

Launch Readiness

Market Insights

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free